Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults With Active Eosinophilic Esophagitis (The "EvolvE" Study)
NCT05774184 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults With Active Eosinophilic Esophagitis (The "EvolvE" Study)
- Lead sponsor
- Celldex Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 1, 2023
- Completion date
- January 23, 2026
- Enrollment
- 86 (actual)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.